Jacobs Levy Equity Management’s Heron Therapeutics HRTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-820,504	Closed	-$1.7M	–	1028
2025 Q2	$1.7M	Buy	+820,504	New	+$1.68M	0.01%	655
2021 Q3	–	Sell	-295,276	Closed	-$4.58M	–	1075
2021 Q2	$4.58M	Sell	295,276 -347,199	-54%	-$5.52M	0.03%	447
2021 Q1	$10.4M	Buy	642,475 +616,717	+2,394%	+$11M	0.08%	289
2020 Q4	$545K	Buy	+25,758	New	+$448K	﹤0.01%	840
2020 Q2	–	Sell	-29,938	Closed	-$351K	–	1089
2020 Q1	$351K	Buy	+29,938	New	+$563K	﹤0.01%	807
2016 Q3	–	Sell	-10,560	Closed	-$191K	–	1065
2016 Q2	$191K	Sell	10,560 -28,100	-73%	-$549K	﹤0.01%	1015
2016 Q1	$734K	Buy	+38,660	New	+$763K	0.02%	639

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's HRTX Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Heron Therapeutics (HRTX) in Q3 2025, closing a stake of 820,504 shares — an estimated $1.7M sold.

Jacobs Levy Equity Management first reported a position in HRTX in Q1 2016 and held it in 7 quarters. The position peaked at $10.4M in Q1 2021. 172 funds tracked by Wall St. Rank hold HRTX as of Q3 2025.

Jacobs Levy Equity Management reported no remaining Heron Therapeutics position as of Q3 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 820,504 Heron Therapeutics shares in Q3 2025, an estimated $1.7M.
Jacobs Levy Equity Management first reported a position in Heron Therapeutics in Q1 2016 and held it in 7 quarters.
Jacobs Levy Equity Management's Heron Therapeutics position peaked at $10.4M in Q1 2021.
172 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.